Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Commitments and Contingent Liabilities (Tables)

v3.20.1
Commitments and Contingent Liabilities (Tables)
12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Royalty Rates
  On net sales of: %

 

  leukemia related products 3.0
  other products 2.5
  in certain limited circumstances, rates may be reduced to 2.0

 

  On fixed sublicense income (with no sublicense income on sales by sub licensee): %

 

  leukemia related products 20.0
  other products 15.0

 

  On fixed sublicense income (with sublicense income on sales by sub licensee): %

 

  leukemia related products 10.0
  other products 7.5